Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Case Report Volume 6 Issue 2

Intravenous Leiomyomatosis of the Uterus: Case Report

Jellouli MA* and Mathis J

Department of Gynecology and Obstetrics, Biel Spitalzentrum, Switzerland

*Corresponding Author: Jellouli MA, Department of Gynecology and Obstetrics, Biel Spitalzentrum, Switzerland.

Received: December 14, 2021; Published: January 10, 2022

Abstract

Intravenous leiomyomatosis (IVL) is a benign and rare pathology, characterized by intravenous proliferation of a histologically benign smooth muscle cell. It can result in systematic complications, especially cardiac, with threatening outcomes if remained untreated.

Intravenous leiomyomatosis (IVL) is probably underestimated, due to a likely easily missed diagnosis.

Introduction: We present a case of an intravenous leiomyomatosis without extra-pelvic involvement, with a brief review of this pathology.

Case Report: A total hysterectomy and bilateral oophorectomy was planned in a 50-year-old woman was because of recurrent pelvic pain with uterus myxomatosis detected in ultrasound. During the surgery, intravenous leiomyomatosis diagnosis was not suspected. Pathological analysis confirmed the unexpected diagnosis. Later, other imaging exams were performed without detecting any extra-pelvic localization. The patient remained with no evidence of disease after 2 years of follow-up.

Conclusion: Although Intravenous leiomyomatosis is rare, it can cause serious complications. Early diagnosis followed by an appropriate treatment (Hysterectomy and oophorectomy or anti-estrogens therapy) are necessary to patient outcome. Further exams and long-term follow-up is needed to exclude systemic metastasis or recurrences.

Keywords: Intravenous Leiomyomatosis; Myomas; Uterus

References

  1. Birch-Hirschfeld FV., et al. “Royal College of Physicians of Edinburgh”. Lehrbuch der Pathologischen Anatomie (1887): 226-258.
  2. Dürck H. “Ueber ein kontinvierlich durch die learned Holvene in das Herz vorwachsendes Fibromyom des Uterus”. Münchener Medizinische Wochenschrift 54 (1907): 1154.
  3. Low H-Y., et al. “Intravenous leiomyomatosis of the uterus: a clinicopathological analysis of nine cases and literature review”. Taiwanese Journal of Obstetrics and Gynecology 56 (2017): 362-365.
  4. E Declas and JP Lucot. “Extra uterine leiomyomatosis: Review of the literature”. Gynécologie Obstétrique Fertilité and Sénologie 47 (2019): 582-590.
  5. Kim Y-N., et al. “Aberrant uterine leiomyomas with extrauterine manifestation: intravenous leiomyomatosis and benign metastasizing leiomyomas”. Obstetrics and Gynecology Science 61 (2018): 509-519.
  6. Qingbo Su., et al. “Intravenous Leiomyomatosis of the Uterus: A Retrospective Single-Center Study in 14 Cases”. Hindawi BioMed Research International (2020).
  7. Valdés Devesa V., et al. “Update on intravenous leiomyomatosis: report of five patients and literature review”. European Journal of Obstetrics and Gynecology and Reproductive Biology 171 (2013): 209-213.
  8. Fornaris RJ., et al. “Multimodality Evaluation of Intravenous Leiomyomatosis: A Rare, Benign but Potentially Life- Threatening Tumor”. American Journal of Case Reports 16 (2015): 794-800.
  9. Nakai G., et al. “Uterine Intravenous Leiomyomatosis with Cardiac Extension: Radiologic Assessment with                Surgical and         Pathologic Correlation”. Case Reports in Obstetrics and Gynecology (2015): 2015 576743.
  10. Vaquero ME., et al. “Uterine smooth-muscle tumors with unusual growth patterns”. The Journal of Minimally Invasive Gynecology 16 (2009): 263-268.
  11. Ma G., et al. “Different surgical strategies of patients with intravenous leiomyomatosis”. Medicine 95 (2016): 37.
  12. Wolfe S., et al. “Perivascular leiomyomatosis: a unique case report”. International Journal of Surgical Pathology 7 (2018): 676-679.
  13. Li R., et al. “Intravenous leiomyomatosis with intracardiac extension: echocardiographic study and literature review”. Texas Heart Institute Journal 41 (2014): 502-506.
  14. Clay TD., et al. “Intravenous leiomyomatosis with intracardiac extension-a review of diagnosis and management with an illustrative case”. Surgical Oncology 22 (2013): e44-52.
  15. Gu X., et al. “Intracardiac leiomyomatosis: clinical findings and detailed echocardiographic features-a Chinese institutional experience”. The Journal of the American Society of Echocardiography 27 (2014): 1011-1016.
  16. Meddeb M., et al. “The heart as a site of metastasis of benign metastasizing leiomyoma: case report and review of the literature”. Case Reports in Cardiology 2018 (2018): 7231326.
  17. Fasih N., et al. “Leiomyomas beyond the uterus: unusual locations, rare manifestations”. Radiographics 28 (2008): 1931-1948.
  18. Mahmoud MS., et al. “Leiomyomas beyond the uterus; benign metastasizing leiomyomatosis with paraaortic metastasizing endometriosis and intravenous leiomyomatosis: a case a case series and review of the literature”. Archives of Gynecology and Obstetrics 291 (2015): 223-230.
  19. Lin J., et al. “Pelvic intravascular leiomyomatosis associated with benign pulmonary metastasizing leiomyoma: clinicopathologic, clonality, and copy number variance analysis”. International Journal of Gynecological Pathology 33 (2014): 140-145.
  20. Harris LM and Karakousis CP. “Intravenous leiomyomatosis with cardiac extension tumor thrombectomy through an abdominal approach”. Journal of Vascular Surgery 31 (2000): 1046-1051.
  21. Mizoguchi C., et al. “Intravenous leiomyomatosis treated with radical hysterectomy and adjuvant aromatase inhibitor therapy”. Journal of Obstetrics and Gynaecology Research 42 (2016): 1405-1408.
  22. Biri A., et al. “Intravenous leiomyomatosis treated with aromatase inhibitor therapy”. International Journal of Gynecology and Obstetrics 101 (2008): 299-300.

Citation

Citation: Jellouli MA and Mathis J. “Intravenous Leiomyomatosis of the Uterus: Case Report”.Acta Scientific Medical Sciences 6.2 (2022): 45-49.

Copyright

Copyright: © 2022 Jellouli MA and Mathis J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US